- Trials with a EudraCT protocol (4)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
4 result(s) found for: Eating Disorder Diagnostic Scale.
Displaying page 1 of 1.
EudraCT Number: 2012-003310-14 | Sponsor Protocol Number: SPD489-344 | Start Date*: 2013-06-18 |
Sponsor Name:Shire Development LLC | ||
Full Title: The SPD489-344, Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose-optimization Study to Evaluate the Efficacy, Safety, and Tolerability of SPD489 in Adults Ag... | ||
Medical condition: Binge eating disorder is characterized by recurrent, distressing episodes of uncontrolled consumption of large amounts of food (binge eating) without the inappropriate compensatory weight loss beha... | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: ES (Prematurely Ended) IT (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2012-003313-34 | Sponsor Protocol Number: SPD489-345 | Start Date*: 2013-03-28 |
Sponsor Name:Shire Development LLC | ||
Full Title: A Phase 3, Multicenter, Open-label, 12-month Extension Safety and Tolerability Study of SPD489 in the Treatment of Adults with Binge Eating Disorder | ||
Medical condition: Binge eating disorder is characterized by recurrent, distressing episodes of uncontrolled consumption of large amounts of food (binge eating) without the inappropriate compensatory weight loss beha... | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: SE (Completed) DE (Completed) IT (Prematurely Ended) ES (Completed) | ||
Trial results: View results |
EudraCT Number: 2012-003309-91 | Sponsor Protocol Number: SPD489-343 | Start Date*: 2013-03-20 |
Sponsor Name:Shire Development, LLC | ||
Full Title: The SPD489-343, Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose-optimization Study to Evaluate the Efficacy, Safety, and Tolerability of SPD489 in Adults Ag... | ||
Medical condition: Binge eating disorder is characterized by recurrent, distressing episodes of uncontrolled consumption of large amounts of food (binge eating) without the inappropriate compensatory weight loss beha... | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: SE (Completed) DE (Completed) ES (Completed) | ||
Trial results: View results |
EudraCT Number: 2022-002757-26 | Sponsor Protocol Number: BH-200-03 | Start Date*: 2023-03-28 | |||||||||||
Sponsor Name:HMNC Holding GmbH | |||||||||||||
Full Title: A 14-week, multicentre, double-blind, randomised, placebo-controlled phase II study with an 8-week treatment period to assess the efficacy and tolerability of a fixed dose of BH-200 (250 mg BID) i... | |||||||||||||
Medical condition: Major Depressive Disorder | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: LT (Trial now transitioned) SK (Trial now transitioned) BG (Trial now transitioned) DE (Ongoing) ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
